Opinion|Videos|August 19, 2024
Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Experts discuss future directions of BTK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s discuss anticipated (or just presented) data from ASCO 2024 on the treatment of CLL. What data or insights are you most looking forward to coming out of ASCO 2024?
- How might emerging biomarkers influence the development and use of BTK inhibitors in CLL?
Advertisement
Related to this article
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
5